Wyeth-Ayerst/Astra’s Dalgan
Executive Summary
Synthetic agonist/antagonist opioid analgesic, approved Dec. 29 and licensed by Wyeht-Ayerst to Astra, will be not be a scheduled drug. Earlier this year, FDA's Drug Abuse Advisory Committee recommended that dezocine be placed in Schedule V of the Controlled Substances Act based on the drug's abuse potential ("The Pink Sheet" Aug. 14, p. 4). Of the four other agonist/antagonist analgesics to reach the U.S., two have been scheduled: Sterling's Talwin and Norwich-Eaton's Buprenex. Dalgan's approval letter states that the company has agreed to "perform a postmarketing surveillance study to assess the incidence of abuse during the first three years of marketing.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.